S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
$4.17
-2.8%
$6.12
$4.00
$14.82
$18.07M0.265,570 shs8,796 shs
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$6.46
+2.5%
$6.15
$3.33
$7.05
$1.22B1.321.87 million shs1.83 million shs
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
$10.09
$10.09
$9.68
$10.15
N/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
$7.21
+0.8%
$7.98
$5.89
$24.81
$442.62M1.211.36 million shs1.14 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
+4.65%-8.71%-33.06%-33.37%-69.24%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-0.40%-8.03%+5.00%+13.92%+48.24%
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
0.00%0.00%0.00%0.00%0.00%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+0.42%-1.79%-16.18%-11.29%-57.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
N/AN/AN/AN/AN/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.5359 of 5 stars
2.32.00.04.90.01.70.6
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/AN/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
4.3668 of 5 stars
3.51.00.04.53.43.31.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
N/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.50
Moderate Buy$7.5016.10% Upside
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
3.00
Buy$37.67422.42% Upside

Current Analyst Ratings

Latest BKD, ATIP, REPL, and LGV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
$699.02M0.03$5.96 per share0.70($23.96) per share-0.17
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$3.02B0.41$0.87 per share7.40$2.15 per share3.00
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$9.80 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
-$69.79M-$31.81N/AN/AN/A-9.98%N/A-6.12%5/13/2024 (Estimated)
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/13/2024 (Estimated)
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
$7.40MN/A0.00N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$174.28M-$3.16N/AN/AN/AN/A-42.94%-35.80%5/16/2024 (Estimated)

Latest BKD, ATIP, REPL, and LGV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/26/2024Q4 2023
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
-$3.17-$2.15+$1.02-$2.15$177.69 million$182.29 million
2/20/2024Q4 2023
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.19-$0.40-$0.21-$0.40N/A$754.48 million
2/8/2024Q3 2024
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.89-$0.77+$0.12-$0.77N/AN/A  

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
N/AN/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/AN/AN/AN/AN/A
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
N/A
1.08
1.08
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
9.40
0.80
0.80
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.16
12.40
12.40

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ATI Physical Therapy, Inc. stock logo
ATIP
ATI Physical Therapy
6,0004.21 million4.17 millionNo Data
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
25,200189.34 million186.50 millionOptionable
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
3N/AN/ANot Optionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
28461.39 million48.74 millionOptionable

BKD, ATIP, REPL, and LGV Headlines

SourceHeadline
Head to Head Survey: Replimune Group (NASDAQ:REPL) vs. CG Oncology (NASDAQ:CGON)Head to Head Survey: Replimune Group (NASDAQ:REPL) vs. CG Oncology (NASDAQ:CGON)
americanbankingnews.com - April 13 at 1:30 AM
Vanguard Group Inc. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)Vanguard Group Inc. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)
marketbeat.com - April 10 at 4:00 AM
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual MeetingInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
globenewswire.com - April 7 at 5:00 PM
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 4 at 8:00 AM
Five things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is tickingFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is ticking
bizjournals.com - March 30 at 9:59 AM
Replimune appoints new CEO ahead of drug applicationReplimune appoints new CEO ahead of drug application
uk.investing.com - March 29 at 12:50 AM
Petri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron deal
bizjournals.com - March 28 at 9:48 AM
Replimune Names Sushil Patel as CEO in Broader ShakeupReplimune Names Sushil Patel as CEO in Broader Shakeup
marketwatch.com - March 26 at 12:12 PM
Replimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEO
markets.businessinsider.com - March 26 at 12:12 PM
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership TransitionsReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
globenewswire.com - March 26 at 7:30 AM
Replimune Group (NASDAQ:REPL) Stock Price Up 5.3%Replimune Group (NASDAQ:REPL) Stock Price Up 5.3%
marketbeat.com - March 21 at 4:24 PM
REPL Apr 2024 10.000 callREPL Apr 2024 10.000 call
finance.yahoo.com - March 16 at 12:31 PM
REPL Mar 2024 10.000 putREPL Mar 2024 10.000 put
finance.yahoo.com - March 15 at 4:28 PM
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
zacks.com - March 11 at 10:56 AM
What Makes Replimune Group, Inc. (REPL) a New Buy StockWhat Makes Replimune Group, Inc. (REPL) a New Buy Stock
zacks.com - March 8 at 1:01 PM
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
finance.yahoo.com - March 6 at 7:31 PM
Replimune to Present at Three Upcoming Investor ConferencesReplimune to Present at Three Upcoming Investor Conferences
finance.yahoo.com - March 5 at 10:04 AM
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
zacks.com - February 23 at 10:56 AM
Positive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy TrialsPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials
markets.businessinsider.com - February 15 at 6:48 PM
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)
markets.businessinsider.com - February 9 at 7:41 AM
Replimune Group Is Worried About This – Should You Be Worried Too?Replimune Group Is Worried About This – Should You Be Worried Too?
msn.com - February 9 at 7:41 AM
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
finance.yahoo.com - February 8 at 11:10 AM
Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash RunwayReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway
finance.yahoo.com - February 8 at 11:10 AM
Replimune Group Inc (REPL)Replimune Group Inc (REPL)
investing.com - February 8 at 12:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

ATI Physical Therapy logo

ATI Physical Therapy

NYSE:ATIP
ATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity evaluation, sports medicine, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in therapy treatments; and sports medicine, including on-site sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI Physical Therapy name. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.
Brookdale Senior Living logo

Brookdale Senior Living

NYSE:BKD
Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.
Longview Acquisition Corp. II logo

Longview Acquisition Corp. II

NYSE:LGV
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
Replimune Group logo

Replimune Group

NASDAQ:REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.